How much funding has Anagenex raised?

Anagenex has raised $37.2M in total funding, most recently a Series A round.

Who are Anagenex's investors?

Anagenex's investors include Lux Capital, Catalio Capital Management, Khosla Ventures, Obvious Ventures.

Where is Anagenex headquartered?

Anagenex is headquartered in South San Francisco.

What industry is Anagenex in?

Anagenex operates in Artificial Intelligence, Biotech, Drug Discovery.

Anagenex

Closed

South San Francisco · Founded 2019 · $37.2M raised

Artificial Intelligence

Biotech

Drug Discovery

Headquarters: South San Francisco
Founded: 2019
Business Model: B2B
Website: anagenex.com

Total Funding: $37.2M
Last Round: $30.0M Series AJun 2022
Rounds: 2

About

Anagenex was a drug discovery company founded in 2019 and headquartered in South San Francisco, California, that combined DNA-encoded library technology with machine learning to identify small-molecule therapeutics via an iterative directed-evolution platform. Led by founder and CEO Nicolas Tilmans, the company closed a $30 million Series A round in 2022 led by Catalio Capital Management to advance its platform. In mid-2025 Anagenex's technology and team were acquired by another AI-driven drug discovery company backed by The Column Group, and its former domain now redirects to unrelated content.

Summary

Anagenex is an Artificial Intelligence company based in South San Francisco, founded in 2019. It has raised $37.2M in total across 2 rounds, most recently a $30.0M Series A round in Jun 2022. Investors include Lux Capital, Catalio Capital Management and Khosla Ventures.